Changchun BCHT Biotechnology Co.

Shanghai Stock Exchange 688276.SS

Changchun BCHT Biotechnology Co. Revenue Per Share for the year ending December 31, 2023: USD 0.62

Changchun BCHT Biotechnology Co. Revenue Per Share is USD 0.62 for the year ending December 31, 2023, a 63.86% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.

Changchun BCHT Biotechnology Co. Revenue Per Share for the year ending December 31, 2022 was USD 0.38, a -17.93% change year over year.
Changchun BCHT Biotechnology Co. Revenue Per Share for the year ending December 31, 2021 was USD 0.46, a -14.33% change year over year.
Changchun BCHT Biotechnology Co. Revenue Per Share for the year ending December 31, 2020 was USD 0.53, a 57.61% change year over year.
Changchun BCHT Biotechnology Co. Revenue Per Share for the year ending December 31, 2019 was USD 0.34, a -18.52% change year over year.

Key data

Date	Revenue Per Share	Dividend Per Share	Free Cash Flow Per Share	Return on Assets (ROA)

Shanghai Stock Exchange: 688276.SS

Changchun BCHT Biotechnology Co.

CEO	Mr. Wei Kong
IPO Date	June 25, 2021
Location	China
Headquarters	1260 Huoju Road
Employees	1,241
Sector	Healthcare
Industries Vaccines Biotechnology Pharmaceuticals

Description

Changchun BCHT Biotechnology Co. Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of human vaccines in China and internationally. Its products include live herpes zoster vaccine; live varicella vaccine; live, nasal, and freeze-dried influenza vaccine; and Rabies vaccine (vero cell) for humans. The company was founded in 2004 and is based in Changchun, China.

Key trends

Past 5 years